The theme: Large-cap drug developers with marketed portfolios and the cash flow to fund the next one — distinct from the pre-revenue end of biotech, where the bet is a trial readout rather than a franchise. Patent cliffs and pipeline depth drive these names more than the economic cycle does.
4 of these also earn a place on the Weight-Loss Drugs list, worth knowing before treating the two as separate bets.
The Pharma group at a glance
Where these companies are filed
The 18 members report under 2 different industries, which is exactly why no standard sector view groups them:
Drug Manufacturers - General14
Drug Manufacturers - Specialty & Generic4
What kind of businesses these are
Average pillar scores across the 18 scored members, against every stock the model scores:
Pillar
Pharma
Market
Read
Quality
71.3
57.7
13.6 above
Growth
49.0
58.0
9.0 below
Value
38.0
38.4
in line
Pillars run 0–100, and Value is judged against sector peers.
Scores run evenly across the group, from LLY at 77.3 down to TAK at 24.1, the median landing mid-pack at 51.6. A theme is a thesis, not a quality filter — membership says a company is exposed to Pharma, and the score says what the model makes of the business.
Where analysts are moving on Pharma
Across the 18 Pharmaceutical names with a reading, the median forward earnings estimate is rising — +1.2% over 90 days, ahead of the market (+0.5%). The split is one-sided: 9 of the 18 moving up against 4 down.
Estimates implied by price ÷ forward P/E, captured together each trading day since June 2026, and outside the Bull Rankings score. How this is measured, across the market →
Common questions
What counts as a Pharmaceutical stock?
Large-cap drug developers with marketed portfolios and the cash flow to fund the next one — distinct from the pre-revenue end of biotech, where the bet is a trial readout rather than a franchise. Patent cliffs and pipeline depth drive these names more than the economic cycle does. The companies are hand-picked by Bartholomew Chupka Jr., the site's founder, from the stocks in our US coverage.
How are the best Pharmaceutical stocks ranked?
Each name is scored on the Bull Rankings quality-growth model — one 0–100 score blending business quality, growth, and valuation — the same score used everywhere on the site.
Are analysts raising or cutting Pharmaceutical earnings estimates?
Across the 18 Pharmaceutical names with a reading, the median forward earnings estimate is rising — +1.2% over 90 days, ahead of the market (+0.5%). The split is one-sided: 9 of the 18 moving up against 4 down. Estimates are implied by price divided by forward P/E, captured together each trading day so only a changed forecast moves the figure, and they sit outside the Bull Rankings score.
How often is the ranking updated?
The universe is re-scored every trading day after the US market close, so the ranking reflects the latest fundamentals and prices.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.